- Home
- VYGR
as 05-09-2025 4:00pm EST
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 191.9M | IPO Year: | 2015 |
| Target Price: | $14.86 | AVG Volume (30 days): | 282.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.75 - $9.55 | Next Earning Date: | 05-06-2025 |
| Revenue: | $66,958,000 | Revenue Growth: | -43.75% |
| Revenue Growth (this year): | -15.67% | Revenue Growth (next year): | 2.04% |
Stock Insider Trading Activity of Voyager Therapeutics Inc. (VYGR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sandrock Alfred | VYGR | President and CEO | Apr 2 '25 | Sell | $3.43 | 10,885 | $37,335.55 | 430,931 | |
| Ferguson Toby | VYGR | Chief Medical Officer | Apr 2 '25 | Sell | $3.43 | 10,086 | $34,594.98 | 157,914 | |
| Sandrock Alfred | VYGR | President and CEO | Feb 20 '25 | Sell | $4.24 | 11,702 | $49,616.48 | 430,931 | |
| Swartz Robin | VYGR | COO & CBO | Feb 20 '25 | Sell | $4.25 | 3,894 | $16,549.50 | 98,397 | |
| Carter Todd Alfred | VYGR | Chief Scientific Officer | Feb 20 '25 | Sell | $4.26 | 3,305 | $14,079.30 | 77,718 | |
| Sandrock Alfred | VYGR | President & CEO | Feb 11 '25 | Sell | $4.45 | 16,644 | $74,065.80 | 430,931 | |
| Fahey Sandell Jacquelyn | VYGR | Chief Legal Officer | Feb 11 '25 | Sell | $4.45 | 4,358 | $19,393.10 | 81,643 | |
| Swartz Robin | VYGR | COO & CBO | Feb 11 '25 | Sell | $4.45 | 6,950 | $30,927.50 | 98,397 | |
| Carter Todd Alfred | VYGR | Chief Scientific Officer | Feb 11 '25 | Sell | $4.45 | 5,413 | $24,087.85 | 77,718 |
Latest Voyager Therapeutics Inc. News
VYGR Breaking Stock News: Dive into VYGR Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
GlobeNewswire
3 days ago
Voyager Reports First Quarter 2025 Financial and Operating Results
GlobeNewswire
11 days ago
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting
GuruFocus.com
18 days ago
Voyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...
GlobeNewswire
a month ago
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
Thomson Reuters StreetEvents
2 months ago
Q4 2024 Voyager Therapeutics Inc Earnings Call
Zacks
2 months ago
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
Associated Press Finance
2 months ago
Voyager Therapeutics: Q4 Earnings Snapshot
Compare VYGR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VYGR Voyager Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.